Personalis presents new clinical results from PREDICT DNA and SCANDARE studies

Personali “announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA blood test for monitoring and predicting neoadjuvant therapy response in triple negative breast cancer, one of the most aggressive types of breast cancer.” “Many triple negative breast cancer patients receive neoadjuvant therapy prior to surgery as standard of care. The data from these two studies independently suggest that an ultrasensitive ctDNA assay like NeXT Personal could help these patients better understand their risk of relapse, with the potential to help inform the need for additional therapy,” said Richard Chen, Chief Medical Officer at Personalis (PSNL). “We believe this data, once published, can form the basis for seeking reimbursement coverage for neoadjuvant therapy monitoring in breast cancer. We are excited to continue to work with leading collaborators to expand the data around the use of NeXT Personal in breast cancer with the goal of helping breast cancer patients optimize their care.”